Sign In
Buy OVID
$2.62
-0.0100 (-0.380%)
At Close: Aug 10, 2026
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
01:01pm, Monday, 06'th Oct 2025
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics Inc. - Special Call
12:52pm, Friday, 03'rd Oct 2025
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
07:05am, Friday, 03'rd Oct 2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issue
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
10:26am, Wednesday, 13'th Aug 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago.
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
08:00am, Wednesday, 13'th Aug 2025
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
08:30am, Wednesday, 23'rd Jul 2025
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
08:00am, Wednesday, 25'th Jun 2025
Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP cost
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
10:15am, Tuesday, 13'th May 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
08:00am, Tuesday, 13'th May 2025
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, ha
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:05am, Tuesday, 06'th May 2025
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
10:10am, Tuesday, 11'th Mar 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
08:00am, Tuesday, 11'th Mar 2025
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move i
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
08:00am, Monday, 03'rd Mar 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant u
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
08:00am, Thursday, 27'th Feb 2025
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today
